These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 26996927)

  • 21. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
    Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY
    Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Versatile strategy for controlling the specificity and activity of engineered T cells.
    Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.
    Lee SY; Olsen P; Lee DH; Kenoyer AL; Budde LE; O'Steen S; Green DJ; Heimfeld S; Jensen MC; Riddell SR; Press OW; Till BG
    J Immunother; 2018 Jan; 41(1):19-31. PubMed ID: 29176334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
    Ormhøj M; Scarfò I; Cabral ML; Bailey SR; Lorrey SJ; Bouffard AA; Castano AP; Larson RC; Riley LS; Schmidts A; Choi BD; Andersen RS; Cédile O; Nyvold CG; Christensen JH; Gjerstorff MF; Ditzel HJ; Weinstock DM; Barington T; Frigault MJ; Maus MV
    Clin Cancer Res; 2019 Dec; 25(23):7046-7057. PubMed ID: 31439577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy.
    Dai Z; Hu X; Jia X; Liu J; Yang Y; Niu P; Hu G; Tan T; Zhou J
    J Cell Physiol; 2021 Aug; 236(8):5832-5847. PubMed ID: 33432627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.
    Sakemura R; Terakura S; Watanabe K; Julamanee J; Takagi E; Miyao K; Koyama D; Goto T; Hanajiri R; Nishida T; Murata M; Kiyoi H
    Cancer Immunol Res; 2016 Aug; 4(8):658-68. PubMed ID: 27329987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
    Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
    J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.
    Johnson LA; Scholler J; Ohkuri T; Kosaka A; Patel PR; McGettigan SE; Nace AK; Dentchev T; Thekkat P; Loew A; Boesteanu AC; Cogdill AP; Chen T; Fraietta JA; Kloss CC; Posey AD; Engels B; Singh R; Ezell T; Idamakanti N; Ramones MH; Li N; Zhou L; Plesa G; Seykora JT; Okada H; June CH; Brogdon JL; Maus MV
    Sci Transl Med; 2015 Feb; 7(275):275ra22. PubMed ID: 25696001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice.
    Liu X; Barrett DM; Jiang S; Fang C; Kalos M; Grupp SA; June CH; Zhao Y
    Blood Cancer J; 2016 Jun; 6(6):e430. PubMed ID: 27258611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma.
    Zhang C; Wang L; Zhang Q; Shen J; Huang X; Wang M; Huang Y; Chen J; Xu Y; Zhao W; Qi Y; Li Y; Ou Y; Yang Z; Qian C
    Front Immunol; 2023; 14():1182409. PubMed ID: 37304295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins.
    Klesmith JR; Su L; Wu L; Schrack IA; Dufort FJ; Birt A; Ambrose C; Hackel BJ; Lobb RR; Rennert PD
    Mol Pharm; 2019 Aug; 16(8):3544-3558. PubMed ID: 31242389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.
    Poirot L; Philip B; Schiffer-Mannioui C; Le Clerre D; Chion-Sotinel I; Derniame S; Potrel P; Bas C; Lemaire L; Galetto R; Lebuhotel C; Eyquem J; Cheung GW; Duclert A; Gouble A; Arnould S; Peggs K; Pule M; Scharenberg AM; Smith J
    Cancer Res; 2015 Sep; 75(18):3853-64. PubMed ID: 26183927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
    Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
    Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Heng G; Jia J; Li S; Fu G; Wang M; Qin D; Li Y; Pei L; Tian X; Zhang J; Wu Y; Xiang S; Wan J; Zhu W; Zhang P; Zhang Q; Peng X; Wang L; Wang P; Wei Z; Zhang Y; Wang G; Chen X; Zhang C; Sun Y; Zhao W; Fan Y; Yang Z; Chen J; Qian C
    Clin Cancer Res; 2020 Apr; 26(7):1606-1615. PubMed ID: 31732519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models.
    Zheng L; Ren L; Kouhi A; Khawli LA; Hu P; Kaslow HR; Epstein AL
    Clin Cancer Res; 2020 Jul; 26(14):3694-3706. PubMed ID: 32273277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of advanced leukemia in mice with mRNA engineered T cells.
    Barrett DM; Zhao Y; Liu X; Jiang S; Carpenito C; Kalos M; Carroll RG; June CH; Grupp SA
    Hum Gene Ther; 2011 Dec; 22(12):1575-86. PubMed ID: 21838572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
    Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single-chain antibody generation system yielding CAR-T cells with superior antitumor function.
    Ochi T; Maruta M; Tanimoto K; Kondo F; Yamamoto T; Kurata M; Fujiwara H; Masumoto J; Takenaka K; Yasukawa M
    Commun Biol; 2021 Mar; 4(1):273. PubMed ID: 33654176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.